Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas.
Company profile
Ticker
RUBY
Exchange
Website
CEO
Pablo Cagnoni
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Rubius Therapeutics Securities Corporation ...
RUBY stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
10 Apr 23
8-K
Departure of Directors or Certain Officers
6 Apr 23
25
Voluntary exchange delisting
28 Mar 23
DEF 14A
Definitive proxy
9 Mar 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Mar 23
PRER14A
Preliminary revised proxy
2 Mar 23
PRE 14A
Preliminary proxy
27 Feb 23
10-K
2022 FY
Annual report
27 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Feb 23
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Feb 23
Transcripts
Latest ownership filings
SC 13G/A
FMR LLC
10 Apr 23
SC 13G/A
BAILLIE GIFFORD & CO
3 Mar 23
4
Dannielle Appelhans
27 Feb 23
SC 13G/A
Flagship VentureLabs IV, LLC
14 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
4
PABLO J CAGNONI
1 Feb 23
4
Dannielle Appelhans
1 Feb 23
4
PABLO J CAGNONI
31 Jan 23
4
Laurence A. Turka
31 Jan 23
SC 13G/A
BAILLIE GIFFORD & CO
20 Jan 23
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 14.92 mm | 14.92 mm | 14.92 mm | 14.92 mm | 14.92 mm | 14.92 mm |
Cash burn (monthly) | 30.18 mm | 17.72 mm | 7.70 mm | 14.87 mm | 10.84 mm | 12.51 mm |
Cash used (since last report) | 471.65 mm | 276.96 mm | 120.31 mm | 232.39 mm | 169.39 mm | 195.53 mm |
Cash remaining | -456.74 mm | -262.04 mm | -105.40 mm | -217.47 mm | -154.47 mm | -180.61 mm |
Runway (months of cash) | -15.1 | -14.8 | -13.7 | -14.6 | -14.3 | -14.4 |
Institutional ownership, Q1 2023
60.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 1 |
Closed positions | 36 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 49.97 mm |
Total shares | 55.04 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Flagship Ventures Fund IV General Partner | 24.22 mm | $0.00 |
Flagship VentureLabs IV | 24.22 mm | $0.00 |
Artal International Management | 3.70 mm | $35.83 mm |
Artal | 2.04 mm | $44.00 k |
State Of Michigan Retirement System | 640.00 k | $13.63 mm |
Acadian Asset Management | 179.68 k | $2.00 k |
Clarius | 21.39 k | $456.00 k |
Simplex Trading | 3.86 k | $0.00 |
Tower Research Capital | 25.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Feb 23 | Dannielle Appelhans | Common Stock | Sell | Dispose S | No | No | 0.1274 | 10,385 | 1.32 k | 0 |
1 Feb 23 | Cagnoni Pablo J | Common Stock | Sell | Dispose S | No | No | 0.25 | 8,448 | 2.11 k | 66,082 |
1 Feb 23 | Dannielle Appelhans | Common Stock | Sell | Dispose S | No | No | 0.25 | 3,878 | 969.50 | 10,385 |
31 Jan 23 | Dannielle Appelhans | Common Stock | Option exercise | Acquire M | No | No | 0 | 7,500 | 0.00 | 14,263 |
31 Jan 23 | Dannielle Appelhans | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 7,500 | 0.00 | 22,500 |
31 Jan 23 | Laurence A. Turka | Common Stock | Sell | Dispose S | No | No | 0.24 | 2,593 | 622.32 | 18,391 |
31 Jan 23 | Laurence A. Turka | Common Stock | Option exercise | Acquire M | No | No | 0 | 8,625 | 0.00 | 20,984 |
31 Jan 23 | Laurence A. Turka | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 8,625 | 0.00 | 25,875 |
31 Jan 23 | Cagnoni Pablo J | Common Stock | Sell | Dispose S | No | No | 0.241 | 7,240 | 1.74 k | 74,530 |
31 Jan 23 | Cagnoni Pablo J | Common Stock | Option exercise | Acquire M | No | No | 0 | 25,000 | 0.00 | 81,770 |